Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $95.25

Shares of Janux Therapeutics, Inc. (NASDAQ:JANXGet Free Report) have been given an average rating of “Buy” by the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $95.25.

Several brokerages have commented on JANX. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th.

Read Our Latest Stock Report on JANX

Insider Buying and Selling

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after purchasing an additional 1,574 shares during the period. US Bancorp DE raised its position in shares of Janux Therapeutics by 2,402.9% in the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after purchasing an additional 1,658 shares during the period. Russell Investments Group Ltd. raised its position in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $59,000. Finally, FNY Investment Advisers LLC raised its position in shares of Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after purchasing an additional 2,425 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

Shares of JANX opened at $23.24 on Friday. The firm’s 50 day moving average is $26.32 and its 200-day moving average is $35.31. The stock has a market capitalization of $1.38 billion, a P/E ratio of -17.09 and a beta of 2.96. Janux Therapeutics has a 12-month low of $22.48 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 9.29%. As a group, equities research analysts forecast that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

(Get Free Report

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Recommended Stories

Analyst Recommendations for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.